Zinc Lozenges for Early Common Cold – Evidence‑Based Recommendations

Efficacy and Dosing

• The European Position Paper on Rhinosinusitis (2020) provides Level Ia evidence that zinc acetate or zinc gluconate lozenges administered at a dose of ≥75 mg elemental zinc per day (e.g., ≥6–7 lozenges) started within the first 24 hours of symptom onset significantly shortens the duration of the common cold in otherwise healthy adults. 1

Timing of Initiation

• Initiation of zinc lozenges must occur within 24 hours of the first cold symptoms to achieve the documented benefit. 1

Duration of Treatment

• The same guideline recommends continuing zinc lozenges for the entire course of the illness until symptoms resolve; stopping after a fixed short period (e.g., 5 days) eliminates the advantage and may even delay recovery. 3

Safety Profile

• Common, non‑serious adverse effects reported with zinc lozenges are bad taste and nausea; moderate‑certainty evidence indicates a modest increase in such events, while serious adverse events are rare. [1][9]

Evidence Quality

• All recommendations above are based on Level Ia evidence (high‑quality systematic reviews and meta‑analyses) from the 2020 European Position Paper on Rhinosinusitis. 1

Alternative or Adjunctive Therapies

Vitamin C

• The European guidelines (Level Ia) note that vitamin C may modestly reduce cold duration and severity on an individual basis, with a favorable safety and cost profile. 10

Antihistamine‑Decongestant‑Analgesic Combinations

• According to the same guideline, combined antihistamine, decongestant, and analgesic therapy provides general symptom relief in adults with the common cold. 8

NSAIDs

• Non‑steroidal anti‑inflammatory drugs are endorsed for relieving pain‑related symptoms (headache, muscle aches) but do not shorten overall cold duration. 10